Children’s asthma attacks reduced and lung function improved by Dupixent in a randomized phase 3 trial
The FINANCIAL -- A pivotal Phase 3 trial of Dupixent® (dupilumab) met its primary and all key secondary endpoints in children ...
ADVERTISEMENT
